drugset / Trial / NCT05197075
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.
Timeline
- Start
- 2022-08-03
- Primary completion
- 2022-09-23
- Completion
- 2022-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobicistat | Small molecule | — | Oral |
| Subject | Darunavir | Small molecule | — | Oral |